文献速递产科母胎医学

在妊娠8-14周采集的血样中测量妊娠相关血浆蛋白A或胎盘生长因子筛查子痫前期

Screening for pre-eclampsia using pregnancy-associated plasma protein-A or placental growth factor measurements in blood samples collected at 8-14 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-03-24

本研究分析丹麦PRESIDE前瞻性多中心研究中8386名孕妇数据,评估孕8-14周血样中妊娠相关血浆蛋白A(PAPP-A)与胎盘生长因子(PlGF)筛查早产子痫前期(PE)的价值。结果显示PAPP-A筛查价值有限,而孕10周后采集的样本中PlGF可显著提高早产PE检出率。

要点

  • 孕10周前采集的血样中,PAPP-A或PlGF联合母体因素筛查早产PE未见显著改善。
  • 孕10周及以后常规血样中,PAPP-A仅轻微提高早产PE检出率。
  • 孕10周及以后PlGF联合母体因素使早产PE检出率从31.3%升至56.3%(10%筛查阳性率下)。

核心结论

  • PAPP-A在孕早期筛查PE中价值有限,而PlGF对孕10-14周早产PE检出率有显著附加价值。

研究设计与样本

  • 本研究分析PRESIDE(丹麦子痫前期筛查)研究数据,该研究为前瞻性、非干预性多中心研究,评估胎儿医学基金会孕早期PE筛查算法在丹麦人群中的预测性能。
  • 研究人群为8386名在孕8-14周采集常规联合孕早期非整倍体筛查血样的孕妇。
  • 常规血样用于检测PAPP-A;多余血清于-80°C储存,分娩后分批检测PlGF;多数孕妇在孕11-14周孕早期超声检查时额外采集血样,所有参与者分娩后分批检测PlGF和PAPP-A。

主要发现

  • 发生早产PE的妊娠中,常规血样PAPP-A中位数的中倍数:孕10周前为0.78(95%CI 0.67-0.90),孕10周为0.80(95%CI 0.58-1.10),孕11-14周为0.64(95%CI 0.53-0.78)。
  • 孕10周前采集的样本中,PAPP-A或PlGF联合母体因素、或联合母体因素+平均动脉压(MAP)+子宫动脉搏动指数(UtA-PI),早产PE检出率均无显著改善。
  • 孕10周及以后常规样本中,PAPP-A仅轻微提高早产PE检出率。
  • 孕10周及以后样本中,PlGF联合母体因素使10%筛查阳性率下早产PE检出率从31.3%(95%CI 16.1-50.0%)升至56.3%(95%CI 37.7-73.6%),提高25.0%(95%CI 4.3-44.4%)。
  • PRESIDE研究中孕11-14周采集的PlGF联合母体因素+MAP+UtA-PI,使10%筛查阳性率下检出率从50.9%(95%CI 37.1-64.6%)升至67.3%(95%CI 53.3-79.3%),提高16.4%(95%CI 5.6-29.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the value of pregnancy-associated plasma protein-A (PAPP-A) in screening for preterm pre-eclampsia (PE) (delivery < 37 weeks' gestation) measured in maternal blood samples collected before 11 weeks, and to compare the screening performance of PAPP-A with that of placental growth factor (PlGF) from blood samples collected at 8-14 weeks. METHODS: This study analyzed data from women who participated in the PRESIDE (Pre-eclampsia Screening in Denmark) study, a prospective, non-interventional multicenter study investigating the predictive performance of the Fetal Medicine Foundation first-trimester screening algorithm for PE in a Danish population. As part of combined first-trimester screening, a routine blood sample was collected at 8-14 weeks' gestation and PAPP-A was measured. Excess serum was stored at -80°C and analyzed for PlGF in batches after delivery. Most women in the PRESIDE study had an extra blood sample collected at the time of the first-trimester scan at 11-14 weeks, which was also analyzed for PlGF and PAPP-A in batches after all the participants had delivered. Screening performance was assessed in terms of the detection rate at a 10% screen-positive rate (SPR) for a combination of PAPP-A or PlGF with maternal factors alone and for a combination of each of these biomarkers with maternal factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI). RESULTS: The study population comprised 8386 women who had a routine combined first-trimester aneuploidy screening blood sample collected at 8-14 weeks' gestation. In pregnancies that developed preterm PE, the median PAPP-A multiples of the median from routine blood samples were 0.78 (95% CI, 0.67-0.90) before 10 weeks, 0.80 (95% CI, 0.58-1.10) at 10 weeks and 0.64 (95% CI, 0.53-0.78) at 11-14 weeks. In women with samples collected before 10 weeks, there was no significant improvement in the detection rate of preterm PE when PAPP-A or PlGF was combined with maternal factors alone or when combined with maternal factors, MAP and UtA-PI. In routine samples collected at or after 10 weeks, PAPP-A only increased the detection rate of preterm PE slightly. However, PlGF in samples collected at or after 10 weeks increased the detection rate from 31.3% (95% CI, 16.1-50.0%) to 56.3% (95% CI, 37.7-73.6%) at a 10% SPR, i.e. an increase in the detection rate of 25.0% (95% CI, 4.3-44.4%), when combined with maternal factors alone. When PlGF collected from the PRESIDE sample at 11-14 weeks was combined with maternal factors, MAP and UtA-PI, there was an increase in the detection rate from 50.9% (95% CI, 37.1-64.6%) to 67.3% (95% CI, 53.3-79.3%), i.e. an increase of 16.4% (95% CI, 5.6-29.0%) at a 10% SPR. CONCLUSIONS: PAPP-A has limited value in first-trimester screening for PE, whereas PlGF adds significantly to the detection rate of preterm PE at 10-14 weeks' gestation. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rode L, Wright A, Wright D, et al. Screening for pre-eclampsia using pregnancy-associated plasma protein-A or placental growth factor measurements in blood samples collected at 8-14 weeks' gestation. Ultrasound Obstet Gynecol. 2025. PMID: 40127386. doi:10.1002/uog.29204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。